Introduction
Currently, ex vivo retroviral stem cell gene therapy is hampered by the low transduction levels of pluripotent hemopoietic stem cells (PHSCs) responsible for repopulating the bone marrow compartment. Amongst the putative factors suspected to limit infection of PHSCs are the expression of the amphotropic GLVR2 virus receptor, the inability to trigger PHSCs into cycle and maintain PHSC properties under ex vivo culture conditions, and the limited contact of PHSCs with virus particles due to Brownian motion. 1 For each of these factors several strategies are under investigation such as the use of new pseudotyped retroviral vectors, growth factor combinations during ex vivo culture and alternative transduction protocols aimed at co-localizing virus and target cells. 2 These approaches have lead to a promising increase in transduced PHSCs of non-human primates to levels of 10-20%. Such levels, although currently only achievable in lethally irradiated recipients, are considered to be clinically relevant for several hemopoietic diseases. 3, 4 Another factor thought to be limiting is the lack of an in vivo growth advantage of genetically corrected cells. One possibility to approach this problem, is the use of bicistronic vectors which contain besides a therapeutic gene, a selectable drug marker. Drug resistance markers which have been used for this purpose are P-glycoprotein-1 (MDR1) and mutants of dihydrofolate reductase (DHFR). Several studies in mice have demonstrated survival upon administration of otherwise lethal concentrations of taxol (MDR1), or methotrexate (DHFR) after infusion of bone marrow genetically modified with retroviral vectors carrying these cDNAs. 5, 6 Recently, it has also been demonstrated that this approach leads to a preferential outgrowth of retrovirus transduced PHSCs in vivo. 7, 8 However, in these latter studies, mice received bone marrow transduced with an ecotropic virus, of which it is known that it efficiently transduces murine PHSCs. Moreover, in these studies a high dosage of trimethotrexate (130 mg/kg) in combination with a thymidine transport inhibitor (NBMPR-P) was administered periodically. NBMPR-P prevents cellular thymidine uptake and thus blocks a natural salvage pathway to circumvent trimethotrexate toxicity. For treatment of a relatively benign disease, such as Gaucher, such a stringent selection procedure poses a high risk and therefore it is questionable whether it can be considered clinically relevant. To test whether in vivo PHSC selection can be achieved starting from a low percentage of transduced hemopoietic cells and by applying a clinically relevant MTX administration schedule, we generated a bicistronic retroviral vector, IG-GC12. This vector carries the human ␤-glucocerebrosidase (hGC) cDNA and a human Phe31Ser mutant, MTX resistant, DHFR cDNA which demonstrates approximately 10 000-fold resistance towards MTX while retaining near to normal biological activity. 9 We have previously reported that the IG-GC12 derived PA125 amphotropic virus can be used successfully for in vitro selection of hemopoietic human cell lines, as well as bone marrow cells derived from mice. 10 Here, we report that infusion of PA125 transduced bone marrow results, after 6 months of MTX selection, in a moderate but significant two-to three-fold increase in hGC expressing cells in peripheral blood and bone marrow of mice that were lethally irradiated before infusion of transduced bone marrow as compared with mice not treated with MTX. Although the effect of MTX selection could be reproduced in mice transplanted up to four times, repeated transplantation of transduced bone marrow alone did not result in significant differences in percentages of hGC expressing cells as compared with a single infusion. These results demonstrate that the MTX selection schedule applied resulted in in vivo selection of retrovirus transduced cells and that repeated administration did not have an additional effect on the number of transduced cells in vivo. In non-ablated mice, in vivo MTX administration after infusion of transduced bone marrow, either or not in combination with multiple infusions, did not result in detectable levels of vector positive cells in bone marrow or peripheral blood. The latter indicates that, using a clinically relevant administration schedule, the selective pressure of MTX is insufficient to achieve a preferential outgrowth of a small number of retrovirus-transduced hemopoietic stem cells in a high background of residing stem cells.
Results

Determination of in vivo MTX toxicity
To determine the effect of MTX on the murine hemopoietic system, male CBA/ca mice were administered a single dose of 10 mg/kg MTX by intraperitoneal injection. Twenty-four hours later mice were killed to determine whether this dose of MTX is sufficiently high to trigger stem cells into proliferation. Therefore, (1) the total number of mononucleated cells (MNCs) was determined in bone marrow and peripheral blood to determine eradication of more differentiated cells. (2) A fixed volume of the bone marrow of MTX-treated and non-treated mice was seeded in methylcellulose to determine killing of more primitive hemopoietic cells. (3) Bone marrow cells were counted after which a fixed number of cells was seeded in methylcellulose to determine whether an enrichment for more primitive cells occurred. As shown in Figure 1 , a single administration of 10 mg/kg MTX resulted in a ± two-fold reduction of MNCs in both bone marrow and peripheral blood. Also, the number of colonies obtained per volume was reduced by a factor of 2. Moreover, by seeding a fixed amount of cells in methylcellulose, a 1.7-fold enrichment in remaining progenitors was observed indicating that cells more primitive than progenitors are triggered into proliferation. Thus, these results illustrate that this dose of MTX is sufficiently toxic to suppress the murine hemopoietic system and enhance proliferation of more primitive hemopoietic cells in vivo. We next investigated the in vivo toxicity of MTX during prolonged exposure. For this purpose, 12 CBA/ca mice were transplanted with 1 × 10 6 unfractionated untransduced bone marrow after having received 9.25 Gy total body irradiation (TBI). These mice were subsequently divided in four groups of three mice each. One group of mice did not receive any MTX whereas mice in the other groups all received 4 mg/kg MTX 2 days after transplantation followed by a dose of 5 mg/kg or 10 mg/kg, or 15 mg/kg twice weekly for 3 months. The effect of MTX administration during hemopoietic reconstitution, shown in Figure 2 , indicated that a MTX dose of 10 mg/kg MTX severely hampered the repopulation of the murine hemopoietic system. However, the mice that successfully engrafted remained healthy for the remainder of the pilot study which indicated that a dose up to 15 mg/kg MTX is sufficiently low to avoid secondary toxicity upon prolonged exposure (data not shown).
In vitro transduction efficiency of murine bone marrow To test the effect of MTX and of multiple infusions of transduced bone marrow cells on the percentages of hGC positive cells, both in marrow-ablated and non-ablated mice, an experimental set up was chosen as is schematically depicted in Table 1 . Mice receiving PA2-transduced bone marrow lacking the MTX resistant DHFR cDNA, groups 1, 2, 7, and 8, served as MTX selection controls. Mice receiving PA125-transduced bone marrow were subdivided according to the number of bone marrow infusions. Mice in groups 3, 4, 9 and 10 received a single infusion of transduced cells, whereas mice in groups 5, 6, 11 and 12 received transduced bone marrow every 2 weeks for a total of four infusions.
For the transplantation of primary female recipients, male bone marrow was harvested every 2 weeks after which the freshly isolated cells were transduced using cocultivation on irradiated PA125 retrovirus producer cells. The in vitro transduction efficiency of these four independent transductions is summarized in Table 2 . The infection efficiency is expressed as (1) percentage progenitors (CFUs) recovered as compared with day 0 CFUs; (2) the fold increase in murine leukocytes that overexpress ␤-glucoside as determined with fluorescein-di-␤-dglucoside flow cytometry; (3) total GC enzyme activity in whole cell lysate as determined with the artificial GC substrate: paranitrophenol ␤-glucoside; and (4) percentages of provirus-positive CFUs without in vitro MTX selection and with in vitro MTX selection. Upon each transduction, bone marrow cells were harvested, counted, washed with PBS, and injected via the tail-vein without any in vitro pre-selection of transduced cells. All nonablated mice survived the infusion of bone marrow.
Of the marrow-ablated mice that did not receive MTX (groups 1, 3 and 5) approximately 70-80% successfully engrafted (data not shown). The survival of mice that were treated with MTX (group 2, 4 and 6) is shown in Figure 3 . These results demonstrate that a moderate protection against MTX during the repopulation phase of the hemopoietic system was conferred by the presence of the mutant DHFR cDNA since 37% (11 mice out of 30) of the mice that received bone marrow transduced with PA125 survived as compared with 10% (one out of 10) of the mice that received PA2-transduced bone marrow. All non-myeloablated recipients, and marrow-ablated mice 
First column: the number of mice groups. Second column: the number of mice per group. Third column: (+) = mice received 9.25 Gy total body irradiation, whereas (−) = no ablative treatment before infusion of bone marrow. Fourth column: virus used to infect bone marrow (PA2 = retrovirus containing the ␤-glucocerebrosidase cDNA only. PA125 = retrovirus containing the ␤-glucocerebrosidase cDNA and the dihydrofolate reductase (DHFR) cDNA). Fifth column: the number of bone marrow infusions. Seventh column: (+) = MTX administered. Ablated mice received 4 mg/kg MTX twice during the first week followed by 10 mg/kg in subsequent weeks. Nonablated mice received 10 mg/kg starting 2 days after transplantation.
that engrafted successfully, remained healthy during the 6 months of MTX administration again confirming the results obtained in the pilot study that the MTX dose and administration schedule applied does not cause secondary toxicity.
In vivo transduction efficiencies
Two months after the first bone marrow transplantation, two mice of groups 3 to 6 and 9 to 12 were killed after which bone marrow and peripheral blood were isolated. From the bone marrow of each mouse 6 × 10 6 cells were used to engraft three secondary recipients that received 8.75 Gy TBI before bone marrow infusion. The secondary recipients were not treated with MTX. Remaining bone marrow and peripheral blood were used to determine the percentage of cells overexpressing GC. Flow cytometric analysis using fluorescein di-␤-d-glucoside showed that in the peripheral blood and bone marrow of myeloablated mice an increase in percentages of GC overexpressing cells could be observed in all transplanted mice as compared with non-transplanted control mice ( Figure 4 ). The increase in GC + cells was the highest in peripheral blood ( Figure 4a ) of mice that received four times transduced cells in combination with MTX (9%), followed by mice receiving a single infusion of transduced cells in combination with MTX (6%). Non-MTX treated mice had lower levels of GC overexpressing cells both after one infusion of bone marrow (2%) or four infusions (4%). In the bone marrow of these mice this effect of MTX was not observed (Figure 4b ) indicating that treatment of MTX during the repopulation phase of the bone marrow compartment did not result in a preferential engraftment of retrovirus-transduced, MTX-resistant, stem cells. This analysis also shows that multiple infusions resulted in a two-to three-fold increase in bone marrow of the total percentage of GC + cells as compared with mice that received a single infusion of transduced cells. However, since at this time point the fourth infusion of transduced bone marrow was administered only 2 weeks before analyses, no distinction can be made between transduced stem cells or transduced progenitors. In non-myeloab- 
Figure 3 The percentage of mice surviving MTX administration the first four weeks after irradiation and transplantation. (२) As an irradiation control, mice (n = 2) received no marrow after irradiation. (ć) Mice receiving bone marrow transduced with PA125. (̆) Mice receiving bone marrow transduced with an amphotropic vector only carrying the hGC cDNA (PA2).
lated mice (groups 9-12) no increase in GC overexpressing cells could be detected either in bone marrow or in peripheral blood cells (data not shown). Six months after BMT all primary recipients were killed. Both bone marrow and peripheral blood was used to determine the percentage of mouse cells expressing the human GC enzyme. For this purpose we used a flow cytometric assay which specifically detects primate GC. 11 The results of this assay, shown for peripheral blood in Figure 5a , demonstrate that mice transplanted once and treated with MTX (group 4, n = 4) contained on average 8 ± 3% hGC + cells which proved significantly higher (P Ͻ 0.05) as compared with mice (group 3, n = 6) transplanted once and not treated with MTX (3 ± 1%). Also, in the peripheral blood of mice that received four times transduced marrow, the effect of MTX on the percentage of hGC + cells could be reproduced in that these mice (group 6, n = 3) contained 12 ± 2% hGC + cells which proved significantly higher (P Ͻ 0.05) as compared with the 5 ± 2% hGC + cells found in the control group (group 5, n = 7). Furthermore, the results showed that the percentages of hGC + cells, present in the peripheral blood of mice that received four times transduced marrow, was not significantly higher (P Ͼ 0.05) as compared with percentages of hGC + cells present in mice that received transduced bone marrow once. In the peripheral blood of nonablated mice no significant increases in percentages of hGC + cells could be detected even in mice that received four times transduced marrow in combination with MTX (group 12, n = 11). The results obtained with the primate GC specific flow cytometric assay on bone marrow is shown in Figure 5b .
Although a similar trend appeared in the bone marrow as observed in the peripheral blood, the effect of MTX treatment failed significance (P Ͼ 0.05) in irradiated mice that received a single infusion of transduced cells (6 ± 4% in non-MTX treated mice as compared with 10 ± 4% in MTX treated mice). However similar to the observations made in peripheral blood, mice transplanted four times and receiving MTX revealed increased percentages of hGC + cells in the bone marrow which proved significantly (P Ͻ 0.05) higher compared with control mice (6 ± 4% in non-MTX-treated mice as compared with 16 ± 3% in MTX-treated mice). Furthermore, also in bone marrow, the increase in hGC + cells obtained after multiple infusions versus a single infusion failed significance and in non-ablated mice no significant changes in percentages of hGC + cells could be detected. With the data obtained, 2 and 6 months after transplantation, we could plot the changes in percentages of hGC Table 1 for treatment schedule of mice in groups 3-6. results in an increase of hGC + cells in time. These data indicated the following: (1) Table 1 group, 2 months after transplantation, a statistical analysis could not be performed and therefore the significance of the increases in GC + cells over time could not be plotted.
To correlate the expression data with the presence of the provirus, bone marrow isolated six months after transplantation from two mice of each group was cultured for 10 days, either in the absence or presence of 2 m MTX. Cells were subsequently harvested and counted, after which a fixed number (1000 cells) of cells was subjected to semi-quantitative PCR analysis for the presence of the hGC cDNA. The results of this experiment are shown in Figure 7 . From this analysis it is suggested that the highest signal was obtained from bone marrow of mice transplanted four times in combination with in vivo MTX treatment (group 6) which demonstrated that, based on the PCR standard, less than 100 vector copies were present in the 1000 cells subjected to PCR. The latter indicates the presence of less than 10% provirus-positive cells. In all other groups the signals were at least a factor of 5 to 10 lower. Culturing of murine bone marrow for 10 days in the presence of MTX before PCR analysis showed that in all mice analyzed provirus-positive cells are present. These measurements also demonstrate the difference in the selective capacity of MTX in vivo versus in vitro since 10 days of in vitro selection, at a lower dose of MTX, much better selects for provirus-positive cells as compared with 6 months in vivo selection. As expected based on the hGC expression data, PCR analyses on bone marrow derived from the non-ablated mice of groups 7-12 (n = 2) was negative in that no provirus could be detected (data not shown).
We also investigated whether we could culture MTXresistant progenitors from the bone marrow of each group of mice (n = 2) to test whether DHFR expression, 6 months after transplantation correlates with hGC expression. Therefore, a fixed volume of bone marrow was cultured for 5 days either in the absence or presence of 2 m MTX after which cells were seeded in 2 ml methyl cellulose to obtain CFUs. By counting the numbers of CFUs obtained in the absence and in the presence of MTX, the percentage of resistant progenitor cells could be determined. The results of this experiment, shown in Figure 8 , demonstrate that the percentages of MTX-resistant CFUs present in bone marrow correlates with the percentages of hGC-expressing cells observed in the bone marrow, indicating that the integrity of the proviral construct was not compromised. In line with the negative hGC expression data, no MTX-resistant CFUs could be cultured from the bone marrow of the non-ablated mice of groups 7 to 12. Table 1 for treatment schedule of mice in groups 1 to 12. Table 1 for treatment schedule of mice in groups 1 to 12.
The secondary recipients were killed 4 months after BMT. These mice all survived 8.25 Gy TBI and BMT and were not administered MTX in an attempt to identify whether the dose of MTX and administration schedule applied for 2 months to the primary recipients resulted in a selection at the stem cell level. Flow cytometric analysis specific for primate GC on either peripheral blood or bone marrow derived from the secondary recipients showed that no hGC + cells could be detected (data not shown). To investigate whether the lack of hGC + cells was at a sensitivity level, we performed PCR on bone marrow derived from the secondary recipients. The results of semi-quantitative PCR and subsequent Southern analysis on bone marrow of each group of mice (n = 3) is shown in Figure 9 . These results demonstrate that vector-positive cells were present in the secondary recipients showing that with the amphotropic virus, bone marrow cells responsible for repopulating the bone marrow compartment were transduced. However, based on a comparison between signal intensities obtained with a standard and the samples tested, the percentage of cells transduced was very low which indicates that 2 months of selection with MTX did not result in significant increases of vector positive cells under the selection conditions applied. The secondary recipients reconstituted with BM derived from non-ablated primary recipients did not demonstrate presence of vector-positive cells either in BM or in peripheral blood (data not shown).
Discussion
We chose an in vivo selection approach in combination with multiple infusions of transduced bone marrow cells because, based on theoretical calculations, even under an optimal transduction efficiency and engraftment it can not be expected that levels of vector-positive PHSCs will exceed 1% in non-ablated recipients. The latter is because only 1% of the total stem cell compartment can be harvested from a patient. It is expected, based on allogeneic BMT studies, that for Gaucher disease at least 20% genetically corrected cells expressing normal levels of GC enzyme will be required to improve the clinical phenotype. 12, 13 Due to current shortcomings of vector technology and the inability to maintain stem cells in vitro such high percentages of genetically corrected cells in vivo are currently not possible. Therefore, to date, mild myeloablative treatment 27 and/or repeated administration of transduced cells and/or in vivo expansion of vector-positive cells using selection with myelosuppressive drugs are required to attempt to achieve clinically relevant levels of transduced PHSCs. Several in vivo selection studies have been performed using a MTX-resistant DHFR. Zhao et al 6 demonstrated that infusion of bone marrow transduced with an amphotropic vector carrying a MTX-resistant DHFR cDNA resulted in increased survival of primary, secondary and tertiary recipients indicating that primitive hemopoietic cells can be protected against otherwise lethal MTX concentrations. Moreover, the authors showed that in vivo administration of MTX resulted in a two-fold increase in vector-positive progenitors as determined by resistance towards neomycine. Allay et al 7, 8 showed that a 5-day treatment with a high dose of trimethotrexate (130 mg/kg) in combination with 20 mg/kg of a thymidine transport inhibitor (NBMPR-P) resulted in highly significant increases in vector positive cells in mice reconstituted with ecotropic retrovirustransduced marrow. The increases, in all blood lineages, from 10 initially up to 90% after progressive drug treatments were specific for the DHFR-containing vector, and were only observed in drug treated mice. However, the latter studies also showed that in mice which contained less than 10% transduced cells selection was less effective using the described selection procedure. When considering an in vivo selection approach several important questions need to be addressed: (1) Can we define a dose of the drug which is high enough to suppress the hemopoietic system and kill non-transduced stem cells with minimal secondary toxicity? (2) Can the drug be administered for prolonged periods of time to patients? (3) Is there a threshold for the number of transduced cells required to obtain successful selection? To address these questions we set up the experiments in mice mimicking a clinically setting. To do so we first investigated what the dose of MTX should be. It is known that a dose of 1 mg/kg MTX can be given orally at a frequency of twice weekly for years to patients suffering from relatively benign diseases such as rheumatoid arthritis without inducing adverse side-effects or severe secondary toxicity.
14 It is generally accepted that normal mice are approximately 10-fold less sensitive towards MTX, presumably because plasma thymidine levels in mice are ± 10-fold higher than in humans. 7, 8 Since cellular thymidine uptake triggers the major salvage pathway through thymidine kinase to circumvent MTX or tri-MTX toxicity 7,8 a dose of 10 mg/kg MTX in mice is likely to be comparable to 1 mg/kg in humans. We then tested whether a dose of 10 mg/kg in mice meets the two requirements outlined above, ie hemopoietic suppression and lack of secondary toxicity upon prolonged exposure. From the results of the pilot study we could conclude that prolonged exposure towards MTX did not have a clear adverse effect on the general health of the mice. Furthermore, the effect of a single injection of MTX showed that at least colony-forming cells in the bone marrow are affected by the treatment of MTX.
We next investigated whether selection occurs in vivo starting from low numbers of retrovirus-transduced cells in myeloablated and non-myeloablated mice. To achieve this, the transduction of mouse bone marrow cells was performed under sub-optimal conditions in an attempt to mimic the low transduction efficiency observed in humans and non-human primates. For this reason, an amphotropic retroviral vector was used which much better reflects in mice, the low transduction efficiency observed in non-human primates, which is, in part, due to low amphotropic receptor expression on murine stem cells as compared with ecotropic receptor levels. 15, 16 Moreover, a limited number (theoretically: ± 5 × 10 4 /kg) of murine PHSCs was infused using unfractionated mouse bone marrow, which reflects percentages of PHSCs that are reinfused in human patients.
Our results indicate that during the repopulation of the hemopoietic system, ie the first 2-3 weeks after marrow ablation, the presence of MTX did not result in a more preferential engraftment of MTX resistant cells, since 2 months after BMT the percentage of GC + cells was similar in mice that did or did not receive MTX. These findings are consistent with studies reported earlier which showed that there was no difference in the presence of provirus positive day-12 colonies of the spleen in irradiated and transplanted mice either or not treated with MTX. 26 These results were further confirmed by our observation that PCR on bone marrow derived from reconstituted secondary recipients showed similar percentages of vector-positive cells in bone marrow of mice treated or not treated with MTX. After 6 months of lowdose MTX treatment, increased percentages of GC + cells in the peripheral blood of primary recipients were found indicating that administration of MTX has an effect either at the stem cell level, at the level of progenitor proliferation, or at the level of cell differentiation. Moreover, in a time span of 4 months, a two-to three-fold increase in GC + cells in both bone marrow and peripheral blood could be observed only in myeloablated mice receiving MTX. These data support the notion that selection for retrovirus-transduced cells does occur using the combination of DHFR and MTX. The finding that the increase was relatively moderate can be explained by the experimental set-up chosen, ie low numbers of transduced stem cells infused, the use of an amphotropic vector and not an ecotropic vector, and the selection schedule applied. Clearly the desired set up of no myeloablation combined with MTX selection did not result in hGC-positive cells in bone marrow or peripheral blood suggesting that the number of transduced cells engrafted, was limiting.
In summary, we have demonstrated that (1) 
Materials and methods
Retroviral vectors and virus producer cell lines
Both the monocistronic IG-GC2 and the bicistronic IG-GC12 retroviral vectors have been described previously. 10, 17 Briefly, IG-GC2 contains only the human hGC cDNA, whereas IG-GC12, contains a hGC cDNA linked via a poliovirus internal ribosomal entry site (IRES) to a human Phe31Ser/Leu158Pro double mutant DHFR cDNA. Both IG-GC2 and IG-GC12 contain a hybrid Moloney murine leukemia virus LTR since the wild-type enhancer in U3 was replaced by a mutant polyoma enhancer, ⌬Mo+PyF101. [17] [18] [19] Generation of both the PA2 (IG-GC2) and PA125 (IG-GC12) amphotropic retrovirus producer cell lines have been described. 10, 17 The PA2 retroviral producer cell line was tested for the absence of RCR using a S + /L − foci assay after amplification on mus dunni cells. The PA125 retroviral producer cell line was tested for the absence of RCR by monitoring reverse transcriptase (RT) activity in infected NIH/3T3 fibroblasts after multiple passages using a fluorimetric RT assay (unpublished results).
Animals and bone marrow transplantation
Male CBA/ca mice, aged 7-8 weeks, were used as bone marrow donors and female CBA/ca mice, aged 10-12 weeks, were used as bone marrow recipients. All mice were obtained from Harlan (Zeist, The Netherlands). Recipients were divided into 12 groups and subjected to the treatment and MTX administration regimen as shown in Table 2 . Mice in groups 1 to 6 received 200 mg/l polymixine B (Genpharma, Maarsen, The Netherlands) and 250 mg/l-ciprofloxacine (Bayer, The Netherlands) via drinking water for 1 week, starting the day after 9.25 Gy total body irradiation (TBI) and bone marrow transplantation (BMT). All recipient mice received 1 × 10 6 unfractionated transduced male bone marrow cells via tail-vein injection. Starting 2 days after BMT, mice in TBI groups 2, 4 and 6 received 4 mg/kg MTX by i.p. injection twice during the first week and 10 mg/kg twice weekly in the following 23 weeks. Starting 2 days after BMT, mice in non-TBI groups 8, 10 and 12 received 10 mg/kg MTX by i.p. injection, twice weekly for a total of 24 weeks. Mice in groups 5, 6, 11 and 12 received 1 × 10 6 freshly isolated and PA125-transduced unfractionated male bone marrow cells every 2 weeks by tail-vein injection for a total of four infusions. Eight weeks after the first BMT, two mice of groups 3 to 6 and 9 to 12 were killed after which 2 × 10 6 bone marrow cells were infused into irradiated (8.75 Gy) secondary CBA/ca female recipients. Primary recipients that successfully engrafted remained healthy during further MTX treatment and were killed 6 months after BMT. Secondary recipients did not receive MTX treatment and were killed 4 months after BMT.
Bone marrow harvest and transduction Bone marrow from male donor mice was harvested by flushing the femurs. Unfractionated bone marrow cells were seeded at a concentration of 1 × 10 6 cells per ml DMEM in the presence of 10 ng/ml mIL-3, 10 ng/ml hIL-1␣, and 0.4 g/ml polybrene. Transduction was performed by seeding BM cells for 72 h on an 80% confluent irradiated (20 Gy) layer of PA125 retroviral producer cells. After 72 h, both adherent and non-adherent cells were harvested, pooled, washed with PBS and injected (0.5 ml) via the tail-vein at a concentration of 2 × 10 6 cells (± 1 × 10 6 bone marrow cells).
In vivo toxicity of MTX MTX was obtained as injection fluid at a concentration of 100 mg/ml (TEVA-Pharma BV, Mijdrecht, The Netherlands). MTX was diluted in PBS and administered by i.p. injection. Normal CBA/ca mice received MTX once after which they were killed 24 h later to determine both bone marrow cellularity and progenitor content. To determine the progenitor content, 10 4 and 10 5 cells were seeded in 2 ml murine methocult M3430 (Stem cell Laboratories, Vancouver, Canada). Numbers of colony-forming units (CFUs) were scored 7-9 days after seeding.
GC enzymatic assays
Flurescein di-␤-d-glucoside flow cytometric analyses to determine percentages of GC + cells was performed as described previously. 20 Flow cytometric analysis utilizing monoclonal antibody 8E4 21 specific for human GC was performed as described. 11 In some assays, murine monoclonal antibodies recognizing hemopoietic subsets in mouse bone marrow or peripheral blood were included to test transduction in specific lineages and to discard irradiated PA125 retroviral producer cells from analyses. To determine GC activity in cell lysates both a non-species specific colorimetric GC assay based on 4-nitrophenol-␤-glucoside, as well as a human GC-specific assay utilizing monoclonal antibody 8E4 were employed as described previously. 21, 22 DNA analysis High molecular weight DNA was isolated as described by Stewart et al. 23 Preparation of cell lysates for PCR was performed according to van Beusechem et al. 24 The presence of the IG-GC12 provirus was investigated by PCR using oligonucleotides GCo4 (5Јcagcccatgttctaccac-3Ј) and IRo2 (5Ј-cgataccgtcgacctcg-3Ј) which hybridize at the 3Ј-coding domain of the hGC cDNA and at the 5Ј-sequence of the IRES, respectively. Genomic DNA extraction from peripheral blood or bone marrow, electrophoresis, blotting procedures and Southern analysis were performed according to standard techniques. 25 
